

A REVIEW ON ALZHEIMER'S DISEASE: PATHOPHYSIOLOGY AND INVOLVING VARIOUS ALZHEIMER'S DISEASE ASSOCIATED RECEPTORS

Sanjivani Sapatale¹, Rushikesh Jadhav², Kirankumar Dhawale³

^{1,2}Student, Pharmacology department, Sinhgad institute, Pune, Maharashtra, India.

³Professor, Pharmacology department, Sinhgad institute, Pune, Maharashtra, India

ABSTRACT

Alzheimer's disease (AD) is a progressive neurodegenerative disease. Alzheimer's disease, a multifaceted neurological ailment that progresses over time, is the most common cause of dementia in older people. Over the last few years, researchers have worked with humans and animals to uncover receptors linked in Alzheimer's disease, with the goal of better understanding the disease's processes and pathophysiological characteristics. Intracellular neurofibrillary tangles and extracellular amyloid protein deposits are pathological features that contribute to senile plaques. Such receptors are important because blocking or activating them could improve or exacerbate AD symptoms, whether or not they are directly linked to current AD medication. Currently available therapies, such as acetylcholinesterase inhibitors (rivastigmine, galantamine, donepezil) and N-methyl D-aspartate receptor antagonists (memantine), have a minor influence on the condition and are only used to treat late-stage symptoms. While the neuropathological symptoms of Alzheimer's disease are well-known, the mechanism's complexities remain unknown. This lack of understanding of the pathogenic process may be one of the main reasons for the lack of viable treatments to prevent illness start and progression.

Keyword: Alzheimer, Pathophysiology, Alzheimer's disease-associated receptors, risk factors, treatment.

1. INTRODUCTION

Alzheimer's disease (AD) is the most common neurodegenerative disease, accounting for more than 80% of dementia cases in elderly individuals around the world. It is defined by a progressive decline in cognitive function that progresses from episodic memory impairments. It causes progressive mental, behavioural, and functional impairment, as well as a loss of learning ability¹. The younger onset AD population is estimated to be around 200,000 people younger than 65 years old. In 2013, it was estimated that 44 million people worldwide were affected by dementia, with a rapid increase to 136 million predicted by 2050². There are currently no medicines that have been shown to have disease-modifying effects, and Alzheimer's disease remains the most unmet medical need in neurology. Changes in amyloid precursor protein metabolism, tau protein phosphorylation, oxidative stress, poor energetics, mitochondrial dysfunction, inflammation, membrane lipid dysregulation, and neurotransmitter pathway disruption all play a role in the pathogenesis of Alzheimer's disease³. The majority of these clinical characteristics are linked to metabolic abnormalities, and it is now obvious that metabolic dysfunction is a major role in Alzheimer's disease. For example, impaired cerebral glucose uptake occurs decades before cognitive loss appears and is an unchanging hallmark of Alzheimer's disease. Deposition of amyloid- β (A β) plaques surrounding neurons, neurofibrillary tangles, cholinergic deficiency, and other neurotransmitter abnormalities are the key pathological hallmarks of Alzheimer's disease¹. Oxidative stress, obesity, diabetes, hypertension, air pollution, smoking, and hypercholesterolemia are all risk factors. Physical activity and nutritional factors have been demonstrated to be protective and aid in the prevention of it⁴. We employ cerebrospinal fluid biomarkers and positron emission tomography to diagnose it. There are currently two standard pharmacotherapies available for AD which is approved by Food and Drug Administration (FDA) are respectively-acetylcholinesterase inhibitors- tacrine, donepezil, rivastigmine, galantamine and N-methyl-D-aspartate glutamate antagonist (NMDA)-memantine⁵.

1.1. Epidemiology of AD

In the United States and many other countries across the world, Alzheimer's disease is a major public health concern, posing a tremendous health, social, and economical burden on society. According to estimates, 35 million individuals worldwide suffer from Alzheimer's disease or other forms of dementia, with an additional 65 million projected by 2030. There is no single cause for Alzheimer's disease, and various modifiable and non modifiable risk factors have been linked to its development and progression. The most important risk factor for the development of Alzheimer's disease is age. The risk of having Alzheimer's disease rises exponentially with age, roughly doubling every 5 years after the age of 65⁶. The vast majority of people with Alzheimer's disease are 65 or older and have 'late-onset' or 'sporadic' disease (95 percent of all cases). Rare genetic mutations have been linked to the development of Alzheimer's disease (AD) before the age of 65, a condition known as 'early onset' or 'familial' AD (which accounts for about 5% of

all cases)⁷. Autosomal dominant mutations in one of the presenilin genes on chromosomes 1 and 14 or the amyloid precursor protein (APP) gene on chromosome 21 are seen in people with familial types of AD. Furthermore, those with Down's syndrome (trisomy 21) are more likely to have early-onset Alzheimer's disease. The genetics of sporadic Alzheimer's disease are more complicated and poorly understood. The epsilon four allele of the apolipoprotein E (APOE) gene on chromosome 19 has been identified as a risk factor for the development of sporadic AD⁸. Females have a higher prevalence of Alzheimer's disease, which reflects their longer life expectancy⁹. Lower educational attainment has been linked to an increased likelihood of Alzheimer's disease dementia¹⁰, supporting the notion that education helps to strengthen a person's cognitive reserve and resilience to the disease¹⁰. A growing amount of research suggests that cerebrovascular risk factors play a key role in the onset and progression of Alzheimer's disease. Diabetes, hypertension, obesity, and smoking have all been linked to an increased risk of Alzheimer's disease¹¹. A family history of Alzheimer's disease in first-degree relatives, as well as a history of a head injury resulting in loss of consciousness, are both risk factors for the onset of AD¹².

1.2. Pathophysiology of AD

Pathology of Alzheimer disease is not clearly understood yet because it is a polygenic and multifarious complex disease. Because Alzheimer disease is a polygenic and very complicated disease, its pathology is still unknown^{13,14}. The accumulation of proteins over time, proteins that develop plaques around neurons, is the hallmark of Alzheimer's disease. hyperphosphorylation of tau proteins, which results in the formation of neurofibrillary tangles (NFTs), and a decrease in the level of the neurotransmitter ACh¹⁵. Acetylcholine is a neurotransmitter that is produced by cholinergic neurons in the brain. It aids in signal transmission and message delivery in the brain¹⁶. It demonstrates that it has a significant role in memory and learning^{17,18}. The pathogenesis of Alzheimer's disease is associated with the formation of plaques and neurofibrillary tangles (NFTs) in the brain, which results in the degeneration of cholinergic neurons in the hippocampal and cortical areas of the brain, as well as a drop in acetylcholine levels^{19,20,21,22,23}. Cholinergic dysfunction causes uncontrolled signal transmission in the cholinergic system, which is associated with Alzheimer's disease²⁴. Cholinergic dysregulation originates in the basal forebrain and interacts with pathogenic elements of Alzheimer's disease, such as NFTs, inflammation, and oxidative stress, to impair cognition²⁵.




Figure1: Some important Alzheimer's pathologic conditions⁵.

2. ALZHEIMER'S DISEASE-ASSOCIATED RECEPTORS

2.1. N-methyl-d-aspartate receptors

N-methyl-d-aspartate receptors (NMDAR) have a role in CNS development and synaptic plasticity, both of which are necessary for learning and memory. Glutamatergic neurotransmission problems have been linked to cognitive symptoms such as learning and memory difficulties. Synaptic plasticity and neuron survival need excitatory glutaminergic neurotransmission via NMDAR. Excessive glutamate neurotransmitter activation induces cytotoxicity and leads in neuronal damage and death, implying a possible mechanism of neurodegeneration in Alzheimer's disease.

As a result, inhibiting glutamergic neurotransmission mediated by NMDAR receptors can reduce cytotoxicity, avoiding additional damage to neurons and cellular oxidative damage²⁶. As a result, NMDAR antagonists have surfaced as possible medicines for Alzheimer's patients, as the receptor comprises numerous subunits and its versions have a variety of activities in the brain. For example, Conantokine is an NMDA receptor antagonist that aids in the understanding of the importance of NMDA receptor inhibition in the treatment of Alzheimer's disease. Moreover, Memantine, an NMDAR antagonist that specifically prevents NMDAR activity, may be used to block NMDAR activation. Extra synaptic NMDAR function is preserved, but normal neurotransmission is unaffected. However, memantine (and other current medications used to treat AD) only relieve the symptoms and do not alter the disease progression³.

2.2. Nicotinic acetylcholine receptor

In Alzheimer's disease, nicotinic acetylcholine receptors (nAChR) play a role in neuroprotection. Agonists and antagonists of the nAChR have also been demonstrated to improve memory performance. When in vitro and in vivo experiments have been undertaken, nAChR ligands such as cotinine and methyl cyclonite have been linked to brain protection. The muscarinic acetylcholine receptor family (mAChR) and nAChR are also acetylcholine targets in the brain. Because beta-amyloid peptides (A) can interact with these receptors, the nAChR family is compromised in Alzheimer's disease²². Acetylcholine (ACh) is an important component of the central nervous system. In the cytoplasm, the choline acetyltransferase enzyme is responsible for ACh production from acetyl-CoA and choline. In synaptic vesicles, the cholinergic vesicular transporter absorbs the neurotransmitter. Exocytosis allows ACh to enter the synaptic cleft after depolarization, where it can bind to its receptors. The acetylcholinesterase enzyme easily hydrolyzes ACh in the synaptic cleft, generating acetate and choline, which is recycled by the high-affinity choline transporter at the presynaptic nerve terminal. In Alzheimer's disease, cholinergic neurons in the basal forebrain, particularly those that make up Meynert's basal nucleus, are severely impaired. Memory and attention problems are caused by the loss of cholinergic neurons. As a result, medications that target the cholinergic system are a promising treatment option for Alzheimer's patients²⁷.

2.3. Gamma-Aminobutyric Acid receptor

The Gamma-Aminobutyric Acid receptor controls GABA and glutamate release, inhibits Adenylyl Cyclase and the cAMP cascade, and affects learning, memory, and cognition. CGP35348 is a GABA receptor antagonist, and the hippocampus concentration of CGP35348 is critical for improving memory by lowering APP toxicity. Neuronal hyperexcitability in certain parts of the brain or spinal cord occurs in a variety of neurological and psychiatric illnesses, which is caused in part by the loss and/or malfunctioning of GABAergic inhibitory interneurons. Improvements in inhibitory neurotransmission in the affected brain regions may help to alleviate the impairments that come with these illnesses. This perception has changed sparked interest in employing preclinical models of neurological and psychiatric illnesses to investigate the efficiency of GABAergic interneuron transplantation in brain or spinal cord regions with hyperexcitability, GABAergic interneurons scarcity, or impaired inhibitory neurotransmission²⁸. Cortical network hyperactivity and aberrant neuronal oscillations can be caused by faulty GABAergic neuronal activities, resulting in a negative shift in memory processes²⁹. GABAergic cell treatment may help to reduce neurological impairments in preclinical AD models²⁸. GABA levels in the brain and spinal cerebrospinal fluid (SCF) are low in Alzheimer's patients, and these changes are more severe in ApoE4 allele carriers. ApoE4 is linked to increased brain activity during rest and memory activities, which could indicate a problem with GABAergic inhibitory regulation. Furthermore, the strongest AD risk factor is the shift in GABA levels in human SCF with age. As a result, ApoE4 may have a role in the development of Alzheimer's disease, inducing age-related deterioration in GABAergic interneurons³⁰.

2.4. G-protein-coupled receptor 40

The neurological system contains several polyunsaturated fatty acids, such as docosahexaenoic acid (DHA), an omega 3 carboxylic acid. The DHA binds to the G-protein-coupled receptor 40 (GPR40) in the neurological system and protects it. for example, GPR40 can boost synaptic plasticity, neuronal activity, and prevent cell death. GPR40 was proposed as a putative dementia target in this area³¹. The hippocampus, which is essential in learning and spatial memory, is one of the brain locations where the receptor is expressed. However, few research have looked at GPR40's functional role in the brain³². GPR40's functional significance in the AD mice model was investigated in one study. GPR40's functional significance in the AD mice model was investigated in one study. GPR40 treatment increased cognitive function significantly, while GPR40 agonist treatment improved learning and memory skills in multiple tests. GPR40 activation also raised neurotrophic factors levels in hippocampal neurons, including brain-derived neurotrophic factor (BDNF), nerve growth factor (NGF), neurotrophin-3 (NT-3), and neurotrophin-4 (NT-4). These findings imply that GPR40 could be a promising therapeutic target for neurogenesis and neuroprotection in the

treatment and prevention of Alzheimer's disease³². GPR40 agonists have been shown to increase adult neurogenesis, block neuronal apoptosis, and protect nerves and reduce brain damage³¹.

2.5. 5-Hydroxytryptamine 6 receptor

The serotonergic neurotransmitter system has been linked to the development of Alzheimer's disease. Furthermore, because 5HTR6 affects pyramidal neuron migration during corticogenesis. As a result, 5HTR6 is engaged in a variety of functions, including cognition, anxiety, memory, and affective state. It may be added to presently approved "Food and Drug Administration" medicines such as cholinesterase inhibitors and NMDA receptor antagonists. 5HTR6 is also a TOR signalling activator that controls GABAergic, glutamatergic, and cholinergic activities. The 5-hydroxytryptamine 6 receptor (5HTR6) is found in parts of the brain involved in cognitive processes and has been studied as a potential treatment target for Alzheimer's disease symptoms³³. With specific 5HTR6 antagonists, a variety of studies have been undertaken. Glutamate and GABA levels are modulated by these antagonists. As a result, dopamine, Ach and norepinephrine concentrations in the brain rise, which are all compromised in Alzheimer's disease. Furthermore, 5HTR6 agonists have been demonstrated to offer cognitive benefits. Cognitive effects from partial or inverse agonists could be promising^{33,34}. Furthermore, 5HTR6 gene variations can be a genetic risk factor for late-onset AD, and 5HTR6 polymorphisms, such as the C267T polymorphism, may play a role in AD susceptibility³³. However, there are few genetic research that look into the link between Alzheimer's disease and serotonergic system gene polymorphisms.

3. RISK FACTORS

Diabetes, oxidative stress, hypertension, air pollution, hypercholesterolemia, atrial fibrillation, alcohol, smoking, and other genetic, environmental, and dietary risk factors for Alzheimer's disease exist. These risk factors have influenced the development of Alzheimer's disease prevention strategies³⁵.

3.1. Diabetes

Insulin-degrading enzyme acts as an amyloid and insulin cleavage enzyme. Because insulin signalling is reduced in type 2 diabetes, the production of insulin degrading enzyme is reduced, resulting in A buildup and hyperinsulinemia³⁶. It was also shown that insulin and amyloid competed for an insulin-degrading enzyme, lowering A clearance³⁷. Insulin is also thought to influence tau protein phosphorylation, and they all have a role in the aetiology of Alzheimer's disease³⁸.

3.2. Hypertension

Hypertension is a risk factor for a variety of pathological illnesses, including myocardial infarctions, strokes, ischemic white matter lesions, atherosclerosis, and cardiovascular diseases, among others. All of these are linked to Alzheimer's disease³⁹. According to a study, higher midlife systolic blood pressure (160 mmHg) is linked to a higher number of senile plaques and lower brain weight in the hippocampus and neocortex, while higher late-life diastolic blood pressure (95 mmHg) is linked to a higher number of neurofibrillary tangles in the hippocampus⁴⁰.

3.3. Obesity

According to studies, increased cholesterol and saturated fats increase the risk of Alzheimer's disease⁴¹. Obesity is characterised by a continuous mild systemic inflammation that leads to a brain inflammatory process marked by increased cytokine release at first^{42,43}. It is a pro-inflammatory factor in which the cytokines tumour necrosis factor alpha (TNF), interleukin-1beta (IL-1), chemokine, and interleukin-6 (IL-6) play a key role⁴⁴.

3.4. Oxidative Stress

According to multiplén research, oxidative stress appears to have a negative impact on the development of Alzheimer's disease^{45,46}. Reactive oxygen species such as superoxide, hydrogen peroxide, hydroxyl radicals, nitric oxide radicals, and others are produced in an infinite amount during oxidative stress¹⁵. It is linked to the oxidation of nucleic acids, proteins, lipids, and carbohydrates, which causes oxidative damage to these components^{47,48}. Endogenous sources such as mitochondria, cytochrome P450, peroxisomes, etc., antioxidant defences such as vitamins (A, C, and E), glutathione peroxidase, catalase, glutathione, and exogenous sources such as UV, ionising radiations, inflammatory cytokines, and so on are all involved in the production of reactive oxygen species (ROS)⁴⁸. Endogenous sources such as mitochondria, cytochrome P450, peroxisomes, etc., antioxidant defences such as vitamins (A, C, and E), glutathione peroxidase, catalase, glutathione, and exogenous sources such as UV, ionising radiations, inflammatory cytokines, and so on are all involved in the production of reactive oxygen species (ROS)⁴⁸.

4. PROTECTIVE FACTORS

4.1. Physical Exercise

Several studies have shown that regular aerobic exercise improves cognitive ability⁴⁹. It is regarded as a useful preventive method for the treatment of various stages of Alzheimer's disease⁵⁰. Physical activity has been shown to increase the amount of neurotrophic factors such as brain-derived neurotrophic factor (BDNF), and their neuroprotective function improves cognition in Alzheimer's disease⁵¹. Exercise can also help to reduce oxidative stress and inflammation. It protects against neurodegeneration and Alzheimer's disease by lowering the damage caused by reactive oxygen species (ROS)^{52,53}. Physical activity also lowers levels of tumour necrosis factor alpha (TNF-) and interleukin-1 alpha (IL-1), which reduces amyloid-induced neuroinflammation in the brain and has a protective effect on cognition or dementia⁵⁴. It also raises the level of nitric oxide in the brain by increasing endothelial nitric oxide synthase activity, which improves neuronal blood flow and reduces brain damage⁵⁵. The cleavage enzymes neprilysin (NEP) and insulin degrading enzymes (IDE) regulate and determine the quantity of amyloid accumulation and protect neurons from amyloid toxicity^{56,56,57}. Physical activity activates IDE and NEP, preventing A build up, which is thought to be the most critical factor in Alzheimer's disease pathogenesis.

4.2. Nutritional Factor

Nutrition appears to be a key preventive factor against Alzheimer's disease⁵⁸. It has been found that a diet high in cholesterol, carbs, and lipids has a negative impact on Alzheimer's disease⁵⁹. It has been discovered that consuming dietary vitamin E without taking additional vitamin E supplements is linked to a lower risk of Alzheimer's disease⁶⁰. Inadequate levels of folate, vitamin B6, and vitamin B12 result in a rise in homocysteine level and concentration, which is linked to AD as a neurotoxic⁶¹.

5. PHARMACOTHERAPY

There are two types of conventional pharmacotherapy for Alzheimer's disease that have been licenced by the Food and Drug Administration (FDA).

- Acetylcholinesterase inhibitors - tacrine, donepezil, rivastigmine, galantamine
- N-methyl-D-aspartate glutamate antagonist (NMDA antagonist)- memantine

5.1. Acetylcholinesterase Inhibitors

According to the cholinergic theory, cognitive dysfunction arises in Alzheimer's patients as a result of significant cholinergic neuron loss, enzymatic failure for ACh generation and degradation, and an inability to transmit neurologic impulses across cholinergic synapses^{62,63}. AChEIs have been hypothesised to improve cholinergic transmission by delaying the breakdown of ACh between synapses¹⁸. They also work by lowering levels of the precursor protein for amyloid, as well as amyloid synthesis and accumulation⁶⁴. To date, the FDA has approved four AChEIs (tacrine, donepezil, rivastigmine, and galantamine) for the treatment of various stages of Alzheimer's disease.

5.2. N-methyl -D- aspartate Glutamate Antagonist (NMDA Antagonist)

NMDA receptors appear to be a promising target for preventing neurodegeneration in Alzheimer's disease⁶⁵. Overactivation of the N-methyl-D-aspartate glutamate (NMDA) receptor allows for excessive Ca²⁺ influx, causing excitotoxicity and resulting in damage and loss of number of neurons⁶⁶. As a result, NMDA antagonist has been a new hope for the treatment of Alzheimer's disease in recent years. Memantine is the first NMDA receptor blocker to receive FDA approval for the treatment of moderate to severe Alzheimer's disease⁶⁷.

6. CONCLUSION AND FUTURE ASPECTS

Alzheimer's disease is a chronic neurodegenerative disease that is rapidly spreading around the world. Because of its complex pathology, variable symptoms, and lack of a specific diagnosis, current therapies such as acetylcholinesterase inhibitors (tacrine, donepezil, rivastigmine, galantamine) and glutamate antagonists (memantine) provide only symptomatic relief and have limited efficacy, there is currently no cure. Because there has been a rapid increase in knowledge about AD etiology and its underlying pathophysiological process in recent years, research in this field has a very broad scope, and a cure for it is still a long way off. Nowadays lots of studies were performed to find the cure for AD. In recent years, several interesting studies have been conducted with some novel options, including as medicines that target amyloid- in various ways. Some current ongoing research approaches for AD are like α secretase promoters, γ -secretase inhibitors, β secretase inhibitors, immunotherapy (anti-amyloid antibodies), etc. So, with so many big advances in the book in the future years, We will be able to deliver more complete and unique pharmacotherapy for Alzheimer's disease thanks to therapeutic agents.

7. REFERENCES

- [1] Kumar A, Singh A, Ekavali. A review on Alzheimer's disease pathophysiology and its management: An update. Pharmacol Reports. 2015;67(2):195-203. doi:10.1016/j.pharep.2014.09.004
- [2] Ahsan F, Ahmad U, Akhtar J. Marine drugs View project Hepatoprotective and Nephroprotective Effects of

- Garcinia kola Heckel Stem Bark Extract and Triterpenoid Fraction Against Sodium Arsenite-Induced Toxicity in Rat Models View project. doi:10.20959/wjpps20166-7045
- [3] Rodríguez E, Arqués JL, Rodríguez R, et al. We are IntechOpen , the world ' s leading publisher of Open Access books Built by scientists , for scientists TOP 1 %. Intech. 1989;32(tourism):137-144. <https://www.intechopen.com/books/advanced-biometric-technologies/liveness-detection-in-biometrics>
- [4] Bondi MW, Edmonds EC, Salmon DP. Alzheimer's disease: Past, present, and future. J Int Neuropsychol Soc. 2017;23(9-10 Special Issue):818-831. doi:10.1017/S135561771700100X
- [5] Campus B. ALZHEIMER'S DISEASE: A COMPREHENSIVE REVIEW Surabhi and B. K. Singh * Department of Pharmaceutical Sciences, Kumaun University, Nainital - 263001, Uttarakhand, India. 2019;10(3):993-1000. doi:10.13040/IJPSR.0975-8232.10(3).993-00
- [6] Prince M, Guerchet M, Prina M. The Epidemiology and Impact of Dementia: Current State and Future Trends. WHO Thematic Briefing. World Heal Organ. Published online 2015.
- [7] International D. World Alzheimer Report 2013 Journey of Caring: An Analysis Of Long-term Care For Dementia - Executive Summary. Published online 2013.
- [8] Querfurth HW, Laferla FM. Alzheimer's Disease. 2010;9:329-344.
- [9] Holtzman DM, Morris JC, Goate AM. Science Translational Medicine Volume 3 issue 77 2011 [doi 10.1126%2Fscitranslmed.3002369] Holtzman, D. M.; Morris, J. C.; Goate, A. M. -- Alzheimer's Disease- The Challenge of the Second Century.pdf. 2011;3(77).
- [10] Reiman EM, Chen K, Alexander GE, et al. Correlations between apolipoprotein E ε4 gene dose and brain-imaging measurements of regional hypometabolism. Proc Natl Acad Sci U S A. 2005;102(23):8299-8302. doi:10.1073/pnas.0500579102
- [11] Hebert LE, Scherr PA, McCann JJ, Beckett LA, Evans DA. Is the risk of developing Alzheimer's disease greater for women than for men? Am J Epidemiol. 2001;153(2):132-136. doi:10.1093/aje/153.2.132
- [12] Stern Y. Cognitive reserve in ageing and Alzheimer's disease. Lancet Neurol. 2012;11(11):1006-1012. doi:10.1016/S1474-4422(12)70191-6
- [13] Huang X, Moir RD, Tanzi RE, Bush AI, Rogers JT. Redox-active metals, oxidative stress, and Alzheimer's disease pathology. Ann N Y Acad Sci. 2004;1012:153-163. doi:10.1196/annals.1306.012
- [14] J, Jończyk J, Panek D, Malawska B. Therapeutic strategies for Alzheimer's disease in clinical trials. Pharmacol Reports. 2016;68(1):127-138. doi:10.1016/j.pharep.2015.07.006
- [15] Mecocci P, Boccardi V, Cecchetti R, et al. A Long Journey into Aging, Brain Aging, and Alzheimer's Disease Following the Oxidative Stress Tracks. J Alzheimer's Dis. 2018;62(3):1319-1335. doi:10.3233/JAD-170732
- [16] Pope CN, Brimijoin S. Cholinesterases and the fine line between poison and remedy. Biochem Pharmacol. 2018;153(December 2017):205-216. doi:10.1016/j.bcp.2018.01.044
- [17] Arjan Blokland. REVIEWS Acetylcholine : a neurotransmitter for learning and memory? Brain Res Rev. 1996;21:285-300.
- [18] Francis PT, Palmer AM, Snape M, Wilcock GK. The cholinergic hypothesis of Alzheimer's disease: A review of progress. J Neurol Neurosurg Psychiatry. 1999;66(2):137-147. doi:10.1136/jnnp.66.2.137
- [19] Arendt T, Brückner MK, Morawski M, Jäger C, Gertz HJ. Early neurone loss in Alzheimer's disease: cortical or subcortical? Acta Neuropathol Commun. 2015;3:10. doi:10.1186/s40478-015-0187-1
- [20] Med CM, Pubmed PM. Beta-amyloid , neuronal death and Alzheimer ' s. Search. Published online 2001:11-12.
- [21] Cholinesterases.Pdf.
- [22] Lombardo S, Maskos U. Role of the nicotinic acetylcholine receptor in Alzheimer's disease pathology and treatment. Neuropharmacology. 2015;96(PB):255-262. doi:10.1016/j.neuropharm.2014.11.018
- [23] Paul S, Jeon WK, Bizon JL, Han JS. Interaction of basal forebrain cholinergic neurons with the glucocorticoid system in stress regulation and cognitive impairment. Front Aging Neurosci. 2015;7(MAR):1-11. doi:10.3389/fnagi.2015.00043
- [24] Kihara T, Shimohama S. Alzheimer's disease and acetylcholine receptors. Acta Neurobiol Exp (Wars). 2004;64(1):99-105.
- [25] Muir JL. Acetylcholine, aging, and Alzheimer's disease. Pharmacol Biochem Behav. 1997;56(4):687-696. doi:10.1016/S0091-3057(96)00431-5
- [26] Wang R, Reddy PH. Role of Glutamate and NMDA Receptors in Alzheimer's Disease. J Alzheimer's Dis. 2017;57(4):1041-1048. doi:10.3233/JAD-160763
- [27] Verma S, Kumar A, Tripathi T, Kumar A. Muscarinic and nicotinic acetylcholine receptor agonists: current

- scenario in Alzheimer's disease therapy. *J Pharm Pharmacol*. 2018;70(8):985-993. doi:10.1111/jphp.12919
- [28] Shetty AK, Bates A. Potential of GABA-ergic cell therapy for schizophrenia, neuropathic pain, and Alzheimers and Parkinsons diseases. *Brain Res*. 2016;1638:74-87. doi:10.1016/j.brainres.2015.09.019
- [29] Sanchez-Mejias E, Nuñez-Diaz C, Sanchez-Varo R, et al. Distinct disease-sensitive GABAergic neurons in the perirhinal cortex of Alzheimer's mice and patients. *Brain Pathol*. 2020;30(2):345-363. doi:10.1111/bpa.12785
- [30] Huang Y, Mucke L. Alzheimer mechanisms and therapeutic strategies. *Cell*. 2012;148(6):1204-1222. doi:10.1016/j.cell.2012.02.040
- [31] Chen JJ, Gong YH, He L. Role of GPR40 in pathogenesis and treatment of Alzheimer's disease and type 2 diabetic dementia. *J Drug Target*. 2019;27(4):347-354. doi:10.1080/1061186X.2018.1491979
- [32] Khan MZ, Zhuang X, He L. GPR40 receptor activation leads to CREB phosphorylation and improves cognitive performance in an Alzheimer's disease mouse model. *Neurobiol Learn Mem*. 2016;131(March):46-55. doi:10.1016/j.nlm.2016.03.006
- [33] Kan R, Wang B, Zhang C, et al. Association of the HTR6 polymorphism C267T with late-onset Alzheimer's disease in Chinese. 2004;372:27-29. doi:10.1016/j.neulet.2004.09.007
- [34] Khoury R, Grysman N, Gold J, et al. The Role of 5 HT6-Receptor Antagonists in Alzheimer's Disease: An Update. *Expert Opin Investig Drugs*. 2018;0(0):1. doi:10.1080/13543784.2018.1483334
- [35] Dominguez E, Chin TY, Chen CP, Wu TY. Management of moderate to severe Alzheimer's disease: Focus on memantine. *Taiwan J Obstet Gynecol*. 2011;50(4):415-423. doi:10.1016/j.tjog.2011.10.004
- [36] Imtiaz B, Tolppanen AM, Kivipelto M, Soininen H. Future directions in Alzheimer's disease from risk factors to prevention. *Biochem Pharmacol*. 2014;88(4):661-670. doi:10.1016/j.bcp.2014.01.003
- [37] Hickman RA, Faustin A, Wisniewski T. Alzheimer Disease and Its Growing Epidemic: Risk Factors, Biomarkers, and the Urgent Need for Therapeutics. *Neurol Clin*. 2016;34(4):941-953. doi:10.1016/j.ncl.2016.06.009
- [38] Arvanitakis Z, Wilson RS, Bienias JL, Evans DA, Bennett DA. Diabetes Mellitus and Risk of Alzheimer Disease and Decline in Cognitive Function. *Arch Neurol*. 2004;61(5):661-666. doi:10.1001/archneur.61.5.661
- [39] Skoog I, Gustafson D. Update on hypertension and Alzheimer's disease. *Neurol Res*. 2006;28(6):605-611. doi:10.1179/016164106X130506
- [40] Petrovitch H, White LR, Izmirlian G, et al. Midlife blood pressure and neuritic plaques, neurofibrillary tangles, and brain weight at death: the HAAS. *Neurobiol Aging*. 2000;21(1):57-62. doi:10.1016/S0197-4580(00)00106-8
- [41] Povova J, Ambroz P, Bar M, et al. Epidemiological of and risk factors for Alzheimer's disease: A review. *Biomed Pap*. 2012;156(2):108-114. doi:10.5507/bp.2012.055
- [42] Gregor MF, Hotamisligil GS. Inflammatory mechanisms in obesity. *Annu Rev Immunol*. 2011;29:415-445. doi:10.1146/annurev-immunol-031210-101322
- [43] Lumeng CN, Saltiel AR. Inflammatory links between obesity and metabolic disease. *J Clin Invest*. 2011;121(6):2111-2117. doi:10.1172/JCI57132
- [44] Alford S, Patel D, Perakakis N, Mantzoros CS. Obesity as a risk factor for Alzheimer's disease: weighing the evidence. *Obes Rev*. 2018;19(2):269-280. doi:10.1111/obr.12629
- [45] Tramutola A, Lanzillotta C, Perluigi M, Butterfield DA. Oxidative stress, protein modification and Alzheimer disease. *Brain Res Bull*. 2017;133:88-96. doi:10.1016/j.brainresbull.2016.06.005
- [46] Barnham KJ, Masters CL, Bush AI. Neurodegenerative diseases and oxidative stress. *Nat Rev Drug Discov*. 2004;3(3):205-214. doi:10.1038/nrd1330
- [47] Mariani E, Polidori MC, Cherubini A, Mecocci P. Oxidative stress in brain aging, neurodegenerative and vascular diseases: An overview. *J Chromatogr B Anal Technol Biomed Life Sci*. 2005;827(1):65-75. doi:10.1016/j.jchromb.2005.04.023
- [48] Markesbery WR. Oxidative stress hypothesis in Alzheimer's disease. *Free Radic Biol Med*. 1997;23(1):134-147. doi:10.1016/S0891-5849(96)00629-6
- [49] Sacco G, Caillaud C, Ben Sadoun G, Robert P, David R, Brisswalter J. Exercise Plus Cognitive Performance over and above Exercise Alone in Subjects with Mild Cognitive Impairment. *J Alzheimer's Dis*. 2016;50(1):19-25. doi:10.3233/JAD-150194
- [50] Cass SP. Alzheimer's disease and exercise: A literature review. *Curr Sports Med Rep*. 2017;16(1):19-22. doi:10.1249/JSR.0000000000000332
- [51] Erickson KI, Miller DL, Roecklein KA. The aging hippocampus: Interactions between exercise, depression,

- and BDNF. *Neuroscientist*. 2012;18(1):82-97. doi:10.1177/1073858410397054
- [52] Majdi A, Mahmoudi J, Sadigh-Eteghad S, Golzari SEJ, Sabermarouf B, Reyhani-Rad S. Permissive role of cytosolic pH acidification in neurodegeneration: A closer look at its causes and consequences. *J Neurosci Res*. 2016;94(10):879-887. doi:10.1002/jnr.23757
- [53] Radak Z, Kumagai S, Taylor AW, Naito H, Goto S. Effects of exercise on brain function: Role of free radicals. *Appl Physiol Nutr Metab*. 2007;32(5):942-947. doi:10.1139/H07-081
- [54] Kang EB, Kwon IS, Koo JH, et al. Treadmill exercise represses neuronal cell death and inflammation during A β -induced ER stress by regulating unfolded protein response in aged presenilin 2 mutant mice. *Apoptosis*. 2013;18(11):1332-1347. doi:10.1007/s10495-013-0884-9
- [55] M. E, K. G, U. L, et al. Mechanisms of Stroke Protection by Physical Activity. *Ann Neurol*. 2003;54(5):582-590. <http://ovidsp.ovid.com/ovidweb.cgi?T=JS&PAGE=reference&D=emed9&NEWS=N&AN=37346064>
- [56] El-Amouri SS, Zhu H, Yu J, Gage FH, Verma IM, Kindy MS. Neprilysin protects neurons against A β peptide toxicity. *Brain Res*. 2007;1152(1):191-200. doi:10.1016/j.brainres.2007.03.072
- [57] Miners JS, Baig S, Palmer J, Palmer LE, Kehoe PG, Love S. A β -degrading enzymes in Alzheimer's disease. *Brain Pathol*. 2008;18(2):240-252. doi:10.1111/j.1750-3639.2008.00132.x
- [58] Nourhashemi F, Gillette-Guyonnet S, Andrieu S, et al. Alzheimer disease: Protective factors. *Am J Clin Nutr*. 2000;71(2). doi:10.1093/ajcn/71.2.643s
- [59] Yusuf M, Weyandt LL, Piryatinsky I. Alzheimer's disease and diet: a systematic review. *Int J Neurosci*. 2017;127(2):161-175. doi:10.3109/00207454.2016.1155572
- [60] Morris MC, Evans DA, Bienias JL, et al. Dietary intake of antioxidant nutrients and the risk of incident Alzheimer disease in a biracial community study. *J Am Med Assoc*. 2002;287(24):3230-3237. doi:10.1001/jama.287.24.3230
- [61] Luchsinger JA, Mayeux R. Reviews Dietary factors and Alzheimer ' s disease. October. 2004;3(October):579-587.
- [62] Jack CR, Albert MS, Knopman DS, et al. Introduction to the recommendations from the National Institute on Aging-Alzheimer's Association workgroups on diagnostic guidelines for Alzheimer's disease. *Alzheimer's Dement*. 2011;7(3):257-262. doi:10.1016/j.jalz.2011.03.004
- [63] Geldenhuys WJ, Darvesh AS. Pharmacotherapy of Alzheimer's disease: Current and future trends. *Expert Rev Neurother*. 2014;15(1):3-5. doi:10.1586/14737175.2015.990884
- [64] Yiannopoulou KG, Papageorgiou SG. Current and future treatments for Alzheimer's disease. *Ther Adv Neurol Disord*. 2013;6(1):19-33. doi:10.1177/1756285612461679
- [65] Chopra K, Misra S, Kuhad A. Current perspectives on pharmacotherapy of Alzheimer's disease. *Expert Opin Pharmacother*. 2011;12(3):335-350. doi:10.1517/14656566.2011.520702
- [66] Sonkusare SK, Kaul CL, Ramarao P. Dementia of Alzheimer's disease and other neurodegenerative disorders - Memantine, a new hope. *Pharmacol Res*. 2005;51(1):1-17. doi:10.1016/j.phrs.2004.05.005
- [67] Van Marum RJ. Update on the use of memantine in Alzheimer's disease. *Neuropsychiatr Dis Treat*. 2009;5(1):237-247. doi:10.2147/ndt.s4048